Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11139354 | 0.86 | CYP3A4 (0.42) | KMT2A | |
| SCHEMBL7069164 | 0.79 | TSHR (0.43) | — | |
| SCHEMBL18245048 | 0.79 | TAAR1 (0.42) | TAAR1HTR2ACYP2A6IDO1PYCR1 | |
| SCHEMBL18427888 | 0.78 | HRH3 (0.41) | TAAR1MAOBHRH3 | |
| SCHEMBL4228681 | 0.78 | CYP2A6 (0.47) | TAAR1HTR2ACYP2A6IDO1PYCR1 | |
| SCHEMBL98012 | 0.75 | TAAR1 (0.50) | TAAR1HTR2ACYP2A6IDO1PYCR1 | |
| SCHEMBL8625033 | 0.74 | HRH3 (0.50) | TAAR1HRH3 | |
| SCHEMBL18770738 | 0.74 | PYCR1 (0.54) | TAAR1HTR2ACYP2A6IDO1PYCR1 | |
| SCHEMBL9818315 | 0.74 | IDO1 (0.39) | TAAR1IDO1 | |
| SCHEMBL910567 | 0.74 | ESR1 (0.57) | TAAR1IDO1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107686475-A | 2,3,5 3 substituted thiophenes, derivative and its synthetic method | 湘潭大学 | 2018-02-13 | — | — | CN | claimed |
| US-7417027-B2 | Linear and cyclic melanocortin receptor-specific peptides | PALATIN TECHNOLOGIES, INC. (US) | 2008-08-26 | — | — | US | claimed |
| EP-1441750-A4 | LINEAR AND CYCLIC MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES | PALATIN TECHNOLOGIES INC (US) | 2006-10-18 | — | — | EP | claimed |
| US-20050038230-A1 | Linear and cyclic melanocortin receptor-specific peptides | PALATIN TECHNOLOGIES, INC. (US) | 2005-02-17 | — | — | US | claimed |
| EP-1126833-A4 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES INC (US) | 2004-09-08 | — | — | EP | claimed |
| EP-1441750-A2 | LINEAR AND CYCLIC MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES | Palatin Technologies, Inc. (US) | 2004-08-04 | — | — | EP | claimed |
| WO-2003006620-A2 | LINEAR AND CYCLIC MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2003-01-23 | — | — | WO | claimed |
| US-6388081-B1 | 4-substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries | LION BIOSCIENCE AG (DE) | 2002-05-14 | — | — | US | claimed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| EP-0977989-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 2000-02-09 | — | — | EP | claimed |
| WO-1998034115-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| WO-1998034111-A1 | TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| EP-0315367-B1 | Polypeptides | ICI PLC (GB) | 1994-04-06 | — | — | EP | claimed |
| US-5068222-A | Polypeptides for treatment of cancer | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-11-26 | — | — | US | claimed |
| US-5049551-A | Antitumor | UBE INDUSTRIES, LTD. (JP) | 1991-09-17 | — | — | US | claimed |
| EP-0400610-A1 | 5-Fluorouracil derivatives | UBE INDUSTRIES, LTD. (JP) | 1990-12-05 | — | — | EP | claimed |
| EP-0263022-B1 | MESOMORPHIC POLYMERS CONTAINING SIDE CHAINS, DERIVED FROM 1-(PHENYL)-2-(4-CYANOPHENYL) ETHANE | THOMSON-CSF (FR) | 1990-11-07 | — | — | EP | claimed |
| EP-0315367-A2 | Polypeptides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-10 | — | — | EP | claimed |
| CN-85102604-A | RESINA-TYPE FLUX OF BRAZING | — | 1985-12-20 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038230-A1 | Linear and cyclic melanocortin receptor-specific peptides | MC1R, MC3R, MC5R | TAAR1 139/4885HTR2A 123/4885CYP2A6 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.